Venosmil capsules 200 mg 60 pcs.

Composition

active ingredient: hidrosmin

1 capsule contains 200 mg of hydrosmin;

excipient: magnesium stearate;

capsule shell: gelatin, erythrosine (E 127), quinoline yellow (E 104), titanium dioxide (E 171).

Release form

Capsules.

Pharmacodynamics. The active substance of venosmil – hydrosmin, according to its chemical structure belongs to the group of flavonoids, is 5,3′-mono-o-(β-hydroxyethyl)-diosmin and 5,3′-di-o-(β-hydroxyethyl)-diosmin. The mechanism of action of hydrosmin has not been fully studied, but may be associated with the inhibition of catecholamine degradation, mainly by inhibiting catecholamine-o-methyltransferase. Four levels of action of hydrosmin can be distinguished:

• a) effect on permeability: reduces capillary permeability and fragility (increased under the influence of histamine, bradykinin and with unbalanced nutrition);
• b) effect on the hemorheological properties of erythrocytes: increases the ability of erythrocytes to deform and reduces blood viscosity;
• c) effect on vein tone: stimulates constant and spontaneous contraction of the smooth muscles of the venous wall;
• d) effect on lymph circulation: hydrosmin causes dilation of lymphatic vessels and increases the speed of lymph flow, thus improving lymph drainage.

Venosmil eliminates the symptoms of chronic (peripheral) venous insufficiency (pain, feeling of heaviness, edema). Gidrosmin has a pronounced effect on the manifestations of venous stasis caused by varicose dilatation of the vessels of the lower extremities.

Pharmacokinetics. After a single oral administration of hydrosmin in healthy volunteers, it was noted that the curve of the drug concentration in the blood plasma in relation to time has a biphasic character. The initial peak of the drug concentration in the blood plasma after administration is observed after 15 minutes, after which the concentration begins to slowly decrease; 4 hours after administration, a new increase in the level is noted with the achievement of an equilibrium concentration after 5-8 hours after administration of the drug, after which the indicators decrease and are practically not detected after 24 hours after administration.

Within 48 hours, 90% of the administered dose of hydrosmin is excreted. The active substance is excreted mainly with feces (80%), 16-18% is excreted with urine.

The drug is used for temporary relief (for 2-3 months) of edema and symptoms associated with chronic venous insufficiency (including hemorrhoids).

The drug is taken orally during meals, washed down with water.

Adults are prescribed 1 capsule (200 mg) 3 times a day (every 8 hours), the duration of treatment is 3 months.

In case of exacerbation of hemorrhoids, 2 capsules (400 mg) are prescribed 3 times a day (every 8 hours), the duration of treatment is 3-4 weeks. Improvement occurs in the 2nd-3rd week of treatment.

The use of the drug for 3 months with breaks in treatment of 1-2 months for 1-2 years may be recommended for patients with chronic venous insufficiency or post-thrombotic syndrome.

Hypersensitivity to the active substance or other components of the drug.

Usually, drug therapy is well tolerated. The most common adverse reactions are:

• Gastrointestinal: epigastric pain, nausea;
• Skin: cracks, itching;
• Central nervous system: weakness, headache.

Pregnancy and breastfeeding

There are no clinical studies of the use of the drug during pregnancy. During preclinical studies, no direct or indirect negative effects on pregnancy or fetal development were identified. The use of the drug during pregnancy is possible only if the expected benefit to the mother outweighs the possible risk to the fetus. There is no data on the penetration of the drug into breast milk, therefore it is not recommended to use it during breastfeeding.

Children

The efficacy and safety of the drug in children have not been established.

Ability to influence reaction speed when driving vehicles or other mechanisms

Does not affect the reaction speed when driving or working with other mechanisms.

Not described. No specific studies of the pharmacokinetics and pharmacodynamics of hydrosmin when used simultaneously with other drugs or food have been conducted.

Due to the good tolerability of venosmila, the possibility of intoxication is practically excluded, even in the event of an overdose.

At temperatures up to 30 °C.